Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | PRF1 | P14222 | 2/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.31 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.31 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.30 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18220268 | 0.93 | APP (0.36) | APPABL1MEN1LMNATNNI3 | |
| SCHEMBL17120676 | 0.92 | APP (0.36) | APPPRF1ABL1 | |
| SCHEMBL17120674 | 0.92 | MAPT (0.37) | APPMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL25609426 | 0.88 | APP (0.40) | APPABL1MEN1LMNATNNI3 | |
| SCHEMBL23134337 | 0.86 | APP (0.37) | APPPRF1ABL1MEN1LMNA | |
| SCHEMBL18220277 | 0.85 | APP (0.36) | APPABL1 | |
| SCHEMBL18220272 | 0.85 | APP (0.37) | APPMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL17099789 | 0.84 | APP (0.46) | APPABL1MEN1LMNATNNI3 | |
| SCHEMBL23123631 | 0.84 | APP (0.46) | APPABL1MEN1LMNATNNI3 | |
| SCHEMBL17595473 | 0.84 | APP (0.46) | APPABL1MEN1LMNATNNI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208916-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2024-06-27 | — | — | US | disclosed |
| US-11718596-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| EP-3119761-B1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | AMYDIS DIAGNOSTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210371390-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2021-12-02 | — | — | US | disclosed |
| US-20210369873-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF TRAUMATIC BRAIN INJURY | Amydis, Inc. | 2021-12-02 | — | — | US | disclosed |
| US-10934264-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200123118-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-04-23 | — | — | US | disclosed |
| US-10370345-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-06 | — | — | US | disclosed |
| US-10005745-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170248616-A1 | IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT | Amydis, Inc. | 2017-08-31 | — | — | US | disclosed |
| US-20160326126-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718596-B2 | Amyloid targeting agents and methods of using the same | APP, CRYAA, APBA1 | APP 1/4885PRF1 3307/4885ABL1 4688/4885 |
| US-20200123118-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, CRYAA, APBA1 | APP 1/4885PRF1 3307/4885ABL1 4688/4885 |
| US-20210369873-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF TRAUMATIC BRAIN INJURY | S100B, FABP7, CRYAB | APP 4/4885PRF1 942/4885ABL1 4317/4885 |
| US-20210371390-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, CRYAA, APBA1 | APP 1/4885PRF1 3307/4885ABL1 4688/4885 |
| US-20240208916-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, CRYAA, APBA1 | APP 1/4885PRF1 3307/4885ABL1 4688/4885 |
| US-20160326126-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, APBA1, CRYAA | APP 1/4885PRF1 3211/4885ABL1 4673/4885 |
| US-10370345-B2 | Amyloid targeting agents and methods of using the same | APP, CRYAA, APBA1 | APP 1/4885PRF1 3307/4885ABL1 4688/4885 |
| US-10934264-B2 | Amyloid targeting agents and methods of using the same | APP, CRYAA, APBA1 | APP 1/4885PRF1 3307/4885ABL1 4688/4885 |
| US-10005745-B2 | Amyloid targeting agents and methods of using the same | APP, APBA1, CRYAA | APP 1/4885PRF1 3211/4885ABL1 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.